BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26821278)

  • 1. Prostate MRSI predicts outcome in radical prostatectomy patients.
    Zakian KL; Hatfield W; Aras O; Cao K; Yakar D; Goldman DA; Moskowitz CS; Shukla-Dave A; Tehrani YM; Fine S; Eastham J; Hricak H
    Magn Reson Imaging; 2016 Jun; 34(5):674-81. PubMed ID: 26821278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse.
    Pucar D; Koutcher JA; Shah A; Dyke JP; Schwartz L; Thaler H; Kurhanewicz J; Scardino PT; Kelly WK; Hricak H; Zakian KL
    Clin Prostate Cancer; 2004 Dec; 3(3):174-81. PubMed ID: 15636684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Magnetic Resonance Spectroscopy Imaging Parameters to Predict Early Biochemical Recurrence after Radical Prostatectomy.
    Parizi MK; Razi A; Alizadeh S; Kasaeian A
    Prague Med Rep; 2019; 120(2-3):74-83. PubMed ID: 31586506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz B; Schnall M; Schultz D; Cote K; Tomaszewski JE; Wein A
    J Urol; 2000 Sep; 164(3 Pt 1):759-63. PubMed ID: 10953141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
    Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
    Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy.
    Zakian KL; Hricak H; Ishill N; Reuter VE; Eberhardt S; Moskowitz CS; Shukla-Dave A; Wang L; Scardino PT; Eastham JA; Koutcher JA
    J Urol; 2010 Dec; 184(6):2320-7. PubMed ID: 20952035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.
    Ravery V; Chastang C; Toublanc M; Boccon-Gibod L; Delmas V; Boccon-Gibod L
    Eur Urol; 2000 Apr; 37(4):449-55. PubMed ID: 10765076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
    Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
    Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Magnetic Resonance Imaging on Prediction of Extraprostatic Extension and Prostatectomy Outcome in Patients with Low-, Intermediate- and High-Risk Prostate Cancer: Try to Find a Standard.
    Radtke JP; Hadaschik BA; Wolf MB; Freitag MT; Schwab C; Alt C; Roth W; Duensing S; Pahernik SA; Roethke MC; Schlemmer HP; Hohenfellner M; Teber D
    J Endourol; 2015 Dec; 29(12):1396-405. PubMed ID: 26154571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
    Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Wright AJ; Barentsz JO; Heerschap A; Scheenen TW
    Eur Urol; 2011 Nov; 60(5):1074-80. PubMed ID: 21419565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
    Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
    Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.
    D'Amico AV; Whittington R; Schnall M; Malkowicz SB; Tomaszewski JE; Schultz D; Wein A
    Cancer; 1995 May; 75(9):2368-72. PubMed ID: 7536124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
    Amsellem-Ouazana D; Younes P; Conquy S; Peyromaure M; Flam T; Debré B; Zerbib M
    Eur Urol; 2005 May; 47(5):582-6. PubMed ID: 15826747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.